Active Implants entered into an exclusive agreement with Geistlich Pharma to be the exclusive Swiss distributor of the company’s NUsurface® Meniscus Prothesis. The world’s first artificial meniscus is now available in Belgium, Germany, Israel, Italy, Switzerland and the U.K.
The relationship between Active Implants and Geistlich Pharma began in 2019 with the launch of the MEFISTO project. The international effort under the prestigious EU Horizon2020 program is designed to develop interventions focused on joint preservation and delaying or preventing joint-sacrificing procedures such as knee replacement, thus reducing the social burden, associated costs and high levels of morbidity resulting from osteoarthritis (OA).
The NUsurface is the first artificial meniscus to be marketed in Europe and is currently under review by FDA. The medial meniscus replacement mimics the function of the natural meniscus and treats pain by redistributing loads transmitted across the knee joint. NUsurface offers patients suffering from meniscus-deficient knee pain a safe and effective surgical alternative to knee replacement, an invasive procedure that is considered the current standard of care for patients unable to get relief from bracing/pain medications or arthroscopic surgery.
Active Implants entered into an exclusive agreement with Geistlich Pharma to be the exclusive Swiss distributor of the company’s NUsurface® Meniscus Prothesis. The world’s first artificial meniscus is now available in Belgium, Germany, Israel, Italy, Switzerland and the U.K.
The relationship between Active Implants and Geistlich Pharma began...
Active Implants entered into an exclusive agreement with Geistlich Pharma to be the exclusive Swiss distributor of the company’s NUsurface® Meniscus Prothesis. The world’s first artificial meniscus is now available in Belgium, Germany, Israel, Italy, Switzerland and the U.K.
The relationship between Active Implants and Geistlich Pharma began in 2019 with the launch of the MEFISTO project. The international effort under the prestigious EU Horizon2020 program is designed to develop interventions focused on joint preservation and delaying or preventing joint-sacrificing procedures such as knee replacement, thus reducing the social burden, associated costs and high levels of morbidity resulting from osteoarthritis (OA).
The NUsurface is the first artificial meniscus to be marketed in Europe and is currently under review by FDA. The medial meniscus replacement mimics the function of the natural meniscus and treats pain by redistributing loads transmitted across the knee joint. NUsurface offers patients suffering from meniscus-deficient knee pain a safe and effective surgical alternative to knee replacement, an invasive procedure that is considered the current standard of care for patients unable to get relief from bracing/pain medications or arthroscopic surgery.
Copy to clipboard 
